Work

PRT2527, a Novel Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, Has Potent Antitumor Activity in Combination with BTK and BCL2 Inhibition in Various Lymphoid Malignancies

Year: 2023

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2023-190093

Authors: Norman Fultang, Ashley M Schwab, Sophia McAneny-Droz, Diane Heiser, Peggy A Scherle, Neha Bhagwat

Institution: Prelude Therapeutics Incorporated (United States)

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4389229781

Cites:

Cited by: 5

Related to: 10